GNMX Aevi Genomic Medicine Inc.

0.22
-0.01  -6%
Previous Close 0.23
Open 0.23
Price To Book 1.03
Market Cap 13963740
Shares 64,766,882
Volume 1,180,486
Short Ratio
Av. Daily Volume 2,368,130

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released January 2, 2019 did not meet primary endpoint.
AEVI-001 (NFC-1)
ADHD
Phase 1b data due mid-2019.
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 data released March 20, 2017 - primary endpoint not met. Subset of data released April 20, 2017 - to be presented April 21, 2017.
NFC-1 - SAGA
mGluR mutation positive ADHD

Latest News

  1. Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth
  2. GNMX: ASCEND Misses Primary Endpoint: GNMX indicates they are not giving up in AEVI-001
  3. The Next Big Biotech Breakout
  4. The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen
  5. Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD
  6. 4 Pharma Stocks Getting a Boost on Thursday (12/20/18)
  7. Aevi Genomic Medicine to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD
  8. GNMX: With ASCEND Enrollment Completed, Read-Out Expected In Q1’19
  9. Aevi Genomic Medicine: 3Q Earnings Snapshot
  10. Aevi Genomic Medicine Reports Third Quarter 2018 Financial Results and Provides Business Update
  11. Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial
  12. Aevi Genomic Medicine to Present at the H.C. Wainwright 20th Annual Global Investment Conference
  13. Aevi Genomic Medicine Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial
  14. Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
  15. GNMX: AEVI Q2 Update: ASCEND Data By Year-End, Enhanced 001 Co-Crystal
  16. Aevi Genomic Medicine Reports Second Quarter 2018 Financial Results and Provides Business Update
  17. Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001